About the Journal

Translational Lung Cancer Research

Aims and Scope

Translational Lung Cancer Research (TLCR, Transl Lung Cancer Res, Print ISSN 2218-6751; Online ISSN 2226-4477) is an international, peer-reviewed, open access journal, which was founded in March 2012. TLCR is indexed by Web of Science [Science Citation Index Expanded (SCIE)], PubMed/PubMed Central, Scopus and the Chemical Abstracts Service (CAS) Databases. It is published quarterly (Mar. 2012 - Jan. 2013), bimonthly (Feb. 2013 - Dec. 2020), monthly (Jan. 2021 -) and openly distributed worldwide. TLCR received its latest impact factor of 4 for the year 2023. It provides practical up-to-date information on prevention, early detection, diagnosis, and treatment of lung cancer and related thoracic diseases. Specific areas of its interest include, but not limited to, multimodality therapy, markers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to lung cancer and relevant thoracic diseases.

TLCR is dedicated to focus on cutting-edge developments at the transition from preclinical to clinical research and thus closes the gap between “bench and bedside”. The aim of TLCR is to provide a forum for the dissemination of original research and review articles in all areas related to lung cancer, as well as a timely platform for the exchange of key opinions between leading experts, and so to provide readers with a novel, well-organized, informative, enlightening and educational journal.

TLCR features a distinguished editorial board, which brings together a team of highly experienced specialists in lung cancer. The diverse experience of the board members allows our editorial panel to lend their expertise to a broad spectrum of lung cancer subjects. The entire submission and review process are managed through the OJS system, an electronic journal system which offers an efficient way and ensures a rapid turnaround of papers submitted for publication. Articles can be published both online and in print when necessary. See more at Information for Authors.


TLCR is endorsed by:

•    Spanish Lung Cancer Group(SLCG);
•    Brazilian Society of Thoracic Surgery (SBCT)

TLCR is the Official Publication of:

•    Society for Translational Medicine (STM), Hong Kong

Indexing

Translational Lung Cancer Research is indexed and covered by

Information for Authors

TLCR is a member of Committee on Publication Ethics (COPE) and it follows the Committee on Publication Ethics (COPE)'s guidelines and the ICMJE recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journal.

Manuscripts submitted must be the original work of the author(s) and must not be published previously or under consideration for publication elsewhere.

Manuscripts Turnaround Time

  • In-house review: 1-3 weeks
  • External peer review: 1-3 months
  • Publication Ahead of Print: within 1 month after being accepted
  • Formal publication: within 1-3 months after being accepted. Original Articles are listed as priority.

Publication Schedule

Published quarterly from Mar. 2012 to Jan. 2013, and bimonthly from Feb. 2013 to Dec. 2020, TLCR now follows a monthly publication model.

Open Access Statement

This journal is a peer reviewed, open access journal. All content of the journal is published under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0). All articles published open access will be immediately and permanently free for all to read, download, copy and distribute as defined by the applied license.

Free access and usage
Permitted third party reuse is defined by the CC BY-NC-ND 4.0 license. This license allows users to copy and distribute the article, provided:

  • this is not done for commercial purposes and further does not permit distribution of the Article if it is changed or edited in any way.
  • the user gives appropriate credit (with a link to the formal publication through the relevant DOI) and provides a link to the license but not in an any way implying that the licensor is endorsing the user or the use of the work.
  • no derivatives including remix, transform, or build upon the material was allowed for distribution.

The full details of the license are available at https://creativecommons.org/licenses/by-nc-nd/4.0/

Copyright

For open access publishing, this journal uses an exclusive licensing agreement. Authors will transfer copyright to AME Publishing Company, but will have the right to share their article in the same way permitted to third parties under the relevant user license, as well as certain scholarly usage rights.

For any inquiry/special circumstance on the copyright, commercial usage or adaptation of TLCR articles, please contact: [email protected]

For reprint order, please contact: [email protected]

Support for Authors to Comply with Funding Body Mandates

We work with authors of research articles supported by funding bodies with open access mandates to ensure that authors can meet their funders’ requirements for public access to research results.

In addition, we offer further support for authors who are required to comply with funding body mandates, including but not limited to:

Editorial Office

Email: [email protected]

Publisher Information

TLCR is published by AME Publishing Company.
Addresses:
Hong Kong branch office: Flat/RM C 16F, Kings Wing Plaza 1, NO. 3 on Kwan Street, Shatin, NT, Hong Kong, China.
Singapore branch office: Pico Creative Centre, 20 Kallang Ave #03-08, 339411 Singapore, Singapore.

 

Updated on July 19, 2024